PacBio 3Q 2026: Revenue $40.56M, EPS ($0.12) — 10-Q Summary

PacBio’s third-quarter revenue rose 6% year over year, while its net loss narrowed slightly. Higher instrument and service revenue lifted sales, but increased cost of revenue—partly from contract manufacturer exit costs, higher memory costs and product transition costs—reduced gross profit.Financia…